Background: The introduction of a new generation of direct acting antiviral agents (DAAs) is a revolution in the treatment of hepatitis C, opening the prospect of eliminating HCV in the future. In Vietnam, the combination of NS5A/NS5B drugs is officially circulated, which has very few studies assessing the therapeutic efficacy and drug tolerance of these drugs in hepatitis C. On the other hand, there are also fewer data on treatment efficiency of patients with genotype 1.6 in the world. Objective: We survey clinical, biochemical and viral response in patients with hepatitis – C, genotype 1,6 treated with the combination of sofosbuvir and ledipasvir (LDV/SOF). Methods: A prospective descriptive study was performed on 48 diagnosed patients who had chronic hepatitis C and/or compensated cirrhosis genotypes 1 or 6 and they were treated for 12 weeks with the combination of sofosbuvir and ledipasvir (LDV/SOF) at Internal Medicine Department, Thu Duc District Hospital. Results: ALT decreased from 72.3 ± 31.9U/L to 29.4 ± 9.3 U/L, AST decreased from 72.9 ± 40.3U/L down to 35.2 ± 23.5 U/L after 12 months of treatment. Albumin and bilirubin maintained 3.64 ± 0.61 g/dL and 0.69 ± 0.26 g/dL. Platelets increase from 145.0 ± 36.3 to 173.9 ± 36.7 after treatment. Percentage of HCV RNA below threshold at the 4-week period later treatment achieved 93.3% and reached 95.5% achieved by SVR12. The incidence of drug side effects is 18.7%. Most are mild, transient symptoms such as fatigue, nausea, diarrhea or loss of appetite... Conclusion: LDV/SOF is an effective, improved interferonfree treatment, good biochemical and microbiological aspects. LDV/SOF therapy is safe and has little effect serious side effects due to medication. Key words: chronic hepatitis C, ledipasvir, sofosbuvir, viral response